Summarised information on offering HCV antibody testing in community pharmacy
A summary of guidance intended to maximise the safety of children and adults with gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID-19 pandemic
This Guidelines summary is based on guidance included within the Children’s Liver Disease Foundation Yellow Alert Pack, written to provide general guidelines on the early identification of liver disease in infants and their referral where appropriate.
A summary of the CLDF's Yellow Alert stool chart—for tracking the colour of newborn babies' stools and being alert to warning signs of prolonged jaundice.
This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040 October 2021
Half-day virtual event focusing on practical approaches to management of gastrointestinal disorders and iron deficiency
Information intended for UK healthcare professionals only. This promotional event has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines.
Date of preparation: July 2021